Medulloepithelioma: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:


'''Medulloepithelioma''' is a rare, primitive, fast-growing [[brain tumour]] thought to stem from [[cell (biology)|cell]]s of the [[embryo]]nic [[medullary cavity]]. Tumours originating in the [[ciliary body]] of the [[human eye|eye]] are referred to as embryonal medulloepitheliomas or [[diktyoma]]s.<ref name="McGraw-Hill Concise Dictionary of Modern Medicine">McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.</ref><ref name="mondofacto.com">[http://www.mondofacto.com/facts/dictionary?Medulloepithelioma Definition of Medulloepithelioma], from Online Medical Dictionary. Retrieved 7 January 2010.</ref>
'''Medulloepithelioma''' is a rare, primitive, fast-growing [[brain tumour]] thought to stem from [[cell (biology)|cell]]s of the [[embryo]]nic [[medullary cavity]]. Tumours originating in the [[ciliary body]] of the [[human eye|eye]] are referred to as embryonal medulloepitheliomas or [[diktyoma]]s.<ref name="McGraw-Hill Concise Dictionary of Modern Medicine">McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.</ref><ref name="mondofacto.com">[http://www.mondofacto.com/facts/dictionary?Medulloepithelioma Definition of Medulloepithelioma], from Online Medical Dictionary. Retrieved 7 January 2010.</ref>
==Historical Perspective==
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
==Classification==
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
:*[group1]
:*[group2]
:*[group3]
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
==Pathophysiology==
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Causes==
* [Disease name] may be caused by either [cause1], [cause2], or [cause3].
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
* There are no established causes for [disease name].
==Differentiating [disease name] from other Diseases==
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
:*[Differential dx1]
:*[Differential dx2]
:*[Differential dx3]
==Epidemiology and Demographics==
* The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
* In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
===Age===
*Patients of all age groups may develop [disease name].
*[Disease name] is more commonly observed among patients aged [age range] years old.
*[Disease name] is more commonly observed among [elderly patients/young patients/children].
===Gender===
*[Disease name] affects men and women equally.
*[Gender 1] are more commonly affected with [disease name] than [gender 2].
* The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
===Race===
*There is no racial predilection for [disease name].
*[Disease name] usually affects individuals of the [race 1] race.
*[Race 2] individuals are less likely to develop [disease name].
==Risk Factors==
*Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
== Natural History, Complications and Prognosis==
*The majority of patients with [disease name] remain asymptomatic for [duration/years].
*Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
*If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
*Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
== Diagnosis ==
===Diagnostic Criteria===
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
:*[criterion 1]
:*[criterion 2]
:*[criterion 3]
:*[criterion 4]
=== Symptoms ===
*[Disease name] is usually asymptomatic.
*Symptoms of [disease name] may include the following:
:*[symptom 1]
:*[symptom 2]
:*[symptom 3]
:*[symptom 4]
:*[symptom 5]
:*[symptom 6]
=== Physical Examination ===
*Patients with [disease name] usually appear [general appearance].
*Physical examination may be remarkable for:
:*[finding 1]
:*[finding 2]
:*[finding 3]
:*[finding 4]
:*[finding 5]
:*[finding 6]
=== Laboratory Findings ===
*There are no specific laboratory findings associated with [disease name].
*A  [positive/negative] [test name] is diagnostic of [disease name].
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*[Imaging study 1] is the imaging modality of choice for [disease name].
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
== Treatment ==
=== Medical Therapy ===
*There is no treatment for [disease name]; the mainstay of therapy is supportive care.
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
*[Medical therapy 1] acts by [mechanism of action1].
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
=== Surgery ===
*Surgery is the mainstay of therapy for [disease name].
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
=== Prevention ===
*There are no primary preventive measures available for [disease name].
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
==References==
{{Reflist|2}}
[[Category: Oncology]]

Revision as of 19:47, 29 April 2016

WikiDoc Resources for Medulloepithelioma

Articles

Most recent articles on Medulloepithelioma

Most cited articles on Medulloepithelioma

Review articles on Medulloepithelioma

Articles on Medulloepithelioma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Medulloepithelioma

Images of Medulloepithelioma

Photos of Medulloepithelioma

Podcasts & MP3s on Medulloepithelioma

Videos on Medulloepithelioma

Evidence Based Medicine

Cochrane Collaboration on Medulloepithelioma

Bandolier on Medulloepithelioma

TRIP on Medulloepithelioma

Clinical Trials

Ongoing Trials on Medulloepithelioma at Clinical Trials.gov

Trial results on Medulloepithelioma

Clinical Trials on Medulloepithelioma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Medulloepithelioma

NICE Guidance on Medulloepithelioma

NHS PRODIGY Guidance

FDA on Medulloepithelioma

CDC on Medulloepithelioma

Books

Books on Medulloepithelioma

News

Medulloepithelioma in the news

Be alerted to news on Medulloepithelioma

News trends on Medulloepithelioma

Commentary

Blogs on Medulloepithelioma

Definitions

Definitions of Medulloepithelioma

Patient Resources / Community

Patient resources on Medulloepithelioma

Discussion groups on Medulloepithelioma

Patient Handouts on Medulloepithelioma

Directions to Hospitals Treating Medulloepithelioma

Risk calculators and risk factors for Medulloepithelioma

Healthcare Provider Resources

Symptoms of Medulloepithelioma

Causes & Risk Factors for Medulloepithelioma

Diagnostic studies for Medulloepithelioma

Treatment of Medulloepithelioma

Continuing Medical Education (CME)

CME Programs on Medulloepithelioma

International

Medulloepithelioma en Espanol

Medulloepithelioma en Francais

Business

Medulloepithelioma in the Marketplace

Patents on Medulloepithelioma

Experimental / Informatics

List of terms related to Medulloepithelioma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Medulloepithelioma is a rare, primitive, fast-growing brain tumour thought to stem from cells of the embryonic medullary cavity. Tumours originating in the ciliary body of the eye are referred to as embryonal medulloepitheliomas or diktyomas.[1][2]

  1. McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
  2. Definition of Medulloepithelioma, from Online Medical Dictionary. Retrieved 7 January 2010.